Japan To Experiment With New NHI Drug Pricing Policy In FY 2010
This article was originally published in PharmAsia News
Executive Summary
TOKYO - A new National Health Insurance drug pricing system that secures prices during patent protection periods but lowers listing prices substantially upon patent expiration will start on an experimental basis beginning April 1
You may also be interested in...
Astellas Pipeline Set For Patent Cliff Rebound
TOKYO - Astellas struggled in 2010 due to generic competition on its blockbusters Prograf (tacrolimus) and Flomax (tamsulosin), but the company's late-stage pipeline looks to put the company in a good position to rebound from its 2010 patent cliff
Astellas Pipeline Set For Patent Cliff Rebound
TOKYO - Astellas struggled in 2010 due to generic competition on its blockbusters Prograf (tacrolimus) and Flomax (tamsulosin), but the company's late-stage pipeline looks to put the company in a good position to rebound from its 2010 patent cliff
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia